Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1. PubMed

Zobrazit více v PubMed

Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400. 10.1016/S0022-5347(05)64153-5 PubMed DOI

Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-57. 10.1200/JCO.2001.19.6.1649 PubMed DOI

Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-71. 10.1002/cncr.11234 PubMed DOI

Klatte T, Gallagher KM, Afferi L, et al. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Med 2019;17:182. 10.1186/s12916-019-1419-1 PubMed DOI PMC

Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490-504. 10.1097/PAS.0b013e318299f0fb PubMed DOI

Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16. 10.1016/S0140-6736(16)00559-6 PubMed DOI PMC

Alaghehbandan R, Perez Montiel D, Luis AS, et al. Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach. Cancers (Basel) 2019;12:8. 10.3390/cancers12010085 PubMed DOI PMC

Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 2014;32:4059-65. 10.1200/JCO.2014.56.5416 PubMed DOI PMC

Stewart-Merrill SB, Thompson RH, Boorjian SA, et al. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. J Clin Oncol 2015;33:4151-7. 10.1200/JCO.2015.61.8009 PubMed DOI

Tan KS, Assel M. The use and drawbacks of risk-grouping in prediction models. BMC Med 2020;18:10. 10.1186/s12916-019-1485-4 PubMed DOI PMC

Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594. 10.1136/bmj.g7594 PubMed DOI

Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol 2015;16:676-85. 10.1016/S1470-2045(15)70167-1 PubMed DOI